Scientific deep-dive

Holding a GLP-1 Before Endoscopy or Surgery: What the Trial Found

A 2026 randomized trial put retained stomach contents at 3.1% when one dose was held against 25.0% when it was not, and found something more useful about the day-before diet.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·4 citations

These drugs slow the stomach deliberately, which is a problem when someone is about to sedate you. In 2026 a randomized trial finally tested what to do about it: patients who held a single dose before an upper endoscopy had clinically significant retained stomach contents 3.1% of the time, against 25.0% for those who continued.[1] The trial was stopped early because the gap crossed its preset stopping boundary. But its most useful finding was about the prep, not the drug, and almost nobody quotes it.

Why a slowed stomach matters here specifically

Sedation removes the reflexes that keep stomach contents out of your airway. Anesthetic fasting rules exist to make sure the stomach is empty by the time that happens, and they were written for stomachs emptying at a normal rate. A drug whose whole mechanism includes slowing gastric emptying can leave food behind after a fast that would ordinarily be sufficient.

The consequences run from inconvenient to serious: an examination the endoscopist cannot complete, a procedure abandoned partway, an unplanned breathing tube, or aspiration.

What the randomized trial found

OCULUS ran at two US referral centers, randomizing adults on a stable GLP-1 or GLP-1/GIP dose to hold one dose before an upper endoscopy or to continue.[1] Its endpoint was a composite of the things that disrupt a procedure: contents preventing examination, premature termination or intubation, or an aspiration event needing extra monitoring or admission.

OCULUS, preplanned interim analysis, 60 patients. Clinically significant residual gastric volume.
GroupRateDifference
Held one dose3.1%—
Continued25.0%21.9 points (90% CI 7.0–36.7), P = .003
Upper endoscopy only — held5.0%—
Upper endoscopy only — continued46.7%41.7 points (90% CI 17.9–65.4), P = .001
Read those numbers with the trial's own caveat attached. This is an interim analysis of 60 patients, and the trial was terminated when the difference crossed a preestablished stopping boundary. Stopping early for benefit is the right thing to do for the participants, but it systematically overstates the size of the effect. The direction is well supported. The precise magnitude is not.

The finding almost nobody quotes

The subgroup having an upper endoscopy plus a colonoscopy had 25 patients, who were therefore on clear liquids the day before as standard bowel prep. Not one of them had clinically significant retained contents, in either the continue arm or the hold arm.[1]

Nobody on clear liquids the day before had a problem, whether they held the drug or not.

The trial's own conclusion draws that out: clear liquids the day prior may mitigate the risk regardless of GLP-1 or GIP use.[1] If that holds up in larger numbers, the practical answer to this whole question may turn out to be a diet instruction rather than a drug hold. That matters, because holding a dose has its own costs for someone whose blood sugar depends on it.

Retained food is not the same as aspiration

This distinction is where most coverage goes wrong. A meta-analysis of 23 studies covering 262,018 patients found GLP-1 users had substantially more retained gastric contents (an odds ratio of 4.54, 95% CI 3.30–6.24) and more procedures terminated early.[2]

And it found no significant difference in aspiration pneumonia.[2] That is the outcome people are frightened of, and across a quarter of a million patients it did not separate.

Both facts are real and they support different actions. Four and a half times the odds of retained contents is a good reason to change how procedures are prepared for. It is not evidence that people on these drugs are being harmed at scale, and a page that reports the first number without the second is telling you half of it.

A second, independent meta-analysis published in Anaesthesia reached the same split from a separate set of studies, which is the strongest form this evidence can currently take.[4] Two teams, different literature searches, same dissociation.

Anaesthesia meta-analysis, 28 observational studies. Both outcomes graded LOW certainty.[4]
OutcomeStudies / patientsOdds ratio (95% CI)
Residual gastric contents despite fasting18 studies, 165,522 patients5.96 (3.96–8.98)
Pulmonary aspiration9 studies, 185,414 patients, 471 cases1.04 (0.87–1.25)

An odds ratio of 1.04 with an interval from 0.87 to 1.25 is about as flat as a result gets. Six times the odds of retained food, and no detectable change in the harm that retained food is feared for.

Does skipping a dose help?

This is the question patients ask, and the same review provides the only pooled answer available. Across five studies and 1,706 patients, withholding at least one dose before a procedure was associated with lower odds of residual gastric contents, with an odds ratio of 0.51 (95% CI 0.33–0.81).[4]

That result is graded very low certainty, the weakest rung there is, and it comes from observational data where the people who skipped a dose differ from those who did not. It is also the only pooled evidence anyone has, it points the way common sense would, and halving the odds of retained contents is a large effect. Whether to skip a dose is a decision for the team doing the procedure, and they need to know you take the drug either way.

What the guidance says, and why it keeps changing

The American Gastroenterological Association issued a Rapid Clinical Practice Update on this, explicitly framed as timely guidance on a fast-moving question rather than a settled standard.[3] Anesthetic and gastroenterological societies in several countries have since published their own, and they do not agree in every detail.

Disagreement is normal for an evidence base whose first randomized trial is still being absorbed. The practical consequence for you is that the instruction you get depends on which society your proceduralist follows.

The one thing to do is tell them. Before any procedure involving sedation (endoscopy, colonoscopy, surgery, dental work under sedation), say that you take a GLP-1, name it, and say when your last dose was. Do not assume it is in your chart, because compounded GLP-1s often never reach the medical record. And do not stop on your own: what to hold and for how long depends on the procedure, the drug and why you are taking it. Our pre-op stop date calendar prints the dates so you can take a specific question to that conversation. A blood thinner has its own stop time on its own label; see blood thinners and a GLP-1.

Frequently Asked Questions

That is your proceduralist's decision, and the guidance differs by society and by procedure. The randomized evidence supports holding: in the OCULUS trial, 3.1% of patients who held one dose had clinically significant retained stomach contents against 25.0% of those who continued. Tell whoever is doing the procedure which drug you take and when your last dose was, and let them decide.
Sedation removes the reflexes that keep stomach contents out of your airway, and fasting rules exist to ensure the stomach is empty by then. Those rules assume normal gastric emptying. These drugs slow it deliberately, so food can remain after a fast that would normally be enough.
It may matter more than holding the dose. In OCULUS, the subgroup also having a colonoscopy, and therefore on clear liquids the day before, had zero cases of clinically significant retained contents in either arm. The trial's authors suggest clear liquids the day prior may mitigate the risk regardless of GLP-1 use.
Not by the largest analysis available. A meta-analysis of 23 studies covering 262,018 patients found 4.54 times the odds of retained gastric contents and more procedures terminated early, but no significant difference in aspiration pneumonia. Retained food and actual harm are different outcomes.
It is the best evidence available and it is small. The published result is a preplanned interim analysis of 60 patients, and the trial was stopped early after the gap crossed a preset stopping boundary. Stopping early for benefit is correct for participants and systematically overstates effect size, so trust the direction more than the exact percentages.

References

  1. 1.Ahmad AI, Garg S, Jacobs J, et al. Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial JAMA Internal Medicine. 2026. PMID: 41837981.
  2. 2.Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis Gastrointestinal Endoscopy. 2025. PMID: 39694296.
  3. 3.Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication Clinical Gastroenterology and Hepatology. 2024. PMID: 37944573.
  4. 4.Elkin J, Rele S, Sumithran P, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis Anaesthesia. 2025. PMID: 40230298.

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Phentermine and a GLP-1 Together: What the Labels and Trials Show

Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.

10 min read

Metformin and a GLP-1 Together: The Risk Is Not the One People Expect

The diabetes trials behind these drugs were largely run on people already taking metformin. Stomach side effects did not stack in the largest analysis, and low blood sugar comes from other drugs. The real overlap is dehydration.

8 min read

GLP-1 Drugs and Rheumatoid Arthritis: One Study, and What It Cannot Tell You

A retrospective review of 215 patients found greater falls in disease activity and pain among those who took a GLP-1 than among those prescribed one who did not. Nearly a third stopped the drug within the year.

6 min read

GLP-1 Drugs After 65: Strength, Not Just Weight

Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.

7 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.4

Wellorithm

7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →